Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Droxia
(United States) [Available] ,Hydrea
(United States) [Available] ,Siklos
(United States) [Available]Synonyms :
Hydroxyurea
Class :
Antineoplastics and Antimetabolite
Brand Name :
Droxia
(United States) [Available] ,Hydrea
(United States) [Available] ,Siklos
(United States) [Available]Synonyms :
Hydroxyurea
Class :
Antineoplastics and Antimetabolite
Dosage Forms & Strengths
Capsule
200 mg
300 mg
400 mg
500 mg
Tablet
100 mg
1000 mg
intermittent therapy:
80
mg/kg
Orally
once every three days, OR
Continuous treatment: 20-30 mg/kg taken orally once a day
Concomitant therapy with irradiation :
80
mg/kg
Orally
once every three days
Continuous Therapy:
20 - 30
mg/kg
Orally
once a day
15
mg/kg
Orally
once a day
15 mg per kg taken orally once a day
500
mg
Orally
twice a day
Dosage Forms & Strengths
Tablet
100 mg
1000 mg
initial dose :
20
mg/kg
Orally
once a day
Increase 5 mg per kg per day every eight weeks depending on the severity <>br
maximum dose: 35 mg/kg per day
The blood counts need to be monitored
bupivacaine: it may increase the risk of methemoglobinemia agents
benzyl alcohol: it may increase the risk of methemoglobinemia agents
capecitabine: it may increase the risk of methemoglobinemia agents
capsaicin: it may increase the risk of methemoglobinemia agents
diphenhydramine: it may increase the risk of methemoglobinemia agents
dyclonine: it may increase the risk of methemoglobinemia agents
estetrol: it may increase the risk of methemoglobinemia agents
furosemide: it may increase the risk of methemoglobinemia agents
levobupivacaine: it may increase the risk of methemoglobinemia agents
lidocaine: it may increase the risk of methemoglobinemia agents
mepivacaine: it may increase the risk of methemoglobinemia agents
nedaplatin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
amiloride: it may increase the risk of methemoglobinemia agents
amitriptyline: it may increase the risk of methemoglobinemia agents
ammonium chloride: it may increase the risk of methemoglobinemia agents
benorilate: it may increase the risk of methemoglobinemia agents
benserazide: it may increase the risk of methemoglobinemia agents
benzatropine: it may increase the risk of methemoglobinemia agents
bepotastine: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bisoxatin: it may increase the risk of methemoglobinemia agents
pheneticillin: it may increase the risk of methemoglobinemia associated agents
cinchocaine: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
enoxacin: it may increase the risk of methemoglobinemia associated agents
eravacycline: it may increase the risk of methemoglobinemia associated agents
moricizine: it may increase the risk of methemoglobinemia associated agents
oxybuprocaine: it may increase the risk of methemoglobinemia associated agents
piperazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
ambroxol: it may increase the risk of methemoglobinemia agents
amikacin: it may increase the risk of methemoglobinemia agents
aminophenazone: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
ceforanide: it may increase the risk of methemoglobinemia agents
bicisate: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
bivalirudin: it may increase the risk of methemoglobinemia agents
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of infection  
when both drugs are combined, there may be an increased risk or severity of methemoglobinemia    
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, it may cause methemoglobinemia  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of neutropenia    
when both drugs are combined, there may be an increased risk of developing an infection from the vaccine   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of methemoglobinemia  
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk of severe and potentially life-threatening infections  
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of serious infections    
when both drugs are combined, there may be an increased risk of serious infections   
when both drugs are combined, there may be an increased risk of serious infections
It may enhance the immunosuppressive effects when combined with idecabtagene vicleucel
alogliptin: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
balsalazide: it may increase the risk of methemoglobinemia agents
when both drugs are combined, that may affect the immune system  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects   
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
methemoglobinemia associated agents: they may increase the toxic effect when combined with local anesthetics
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
when both the drugs combine there will be increased risk of myelosuppression.
when both drugs are combined, there may be an increased risk or severity of adverse effects   
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects  
when both drugs are combined, there may be an increased risk or severity of adverse effects   
increases bone marrow suppression
when both drugs are combined, the risk or severity of adverse effects increases  
may increase bone marrow suppression
interaction may increase the risk of bone marrow suppression
interaction may increase the risk of bone marrow suppression
may increase the risk of excessive bone marrow suppression
increases bone marrow suppression
pramoxine /hydrocortisone topicalÂ
may increase the adverse effect
may increase the toxic effect
may increase the toxic effects of local anaesthetics
may increase the toxic effect of local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may increases the adverse effect of Local Anesthetics
may increase the adverse effect of Local Anesthetics
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with prilocaine
sodium thiosulfate & sodium nitriteÂ
may have an increasingly adverse effect when combined with sodium nitrite
may increase the toxic effect of Local Anesthetics
may increase the adverse effects when combined
may have an increasingly adverse effect when combined with methemoglobinemia agents
may increase the adverse effect of local anesthetics
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
dichlorphenamide : it may increase the toxic effect of Methemoglobinemia Associated Agents
cimetidine : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
guanethidine : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
tramadol : it may increase the toxic effect of Methemoglobinemia Associated Agents
azithromycin: it may increase the risk of methemoglobinemia agents
betaine: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
abiraterone: it may increase the risk of methemoglobinemia agents
acetohexamide: it may increase the risk of methemoglobinemia agents
bedaquiline: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
calfactant: it may increase the risk of methemoglobinemia agents
cannabidiol: it may increase the risk of methemoglobinemia agents
penfluridol: it may increase the risk of methemoglobinemia agents
pentoxyverine: it may increase the risk of methemoglobinemia agents
acenocoumarol: it may increase the risk of methemoglobinemia agents
bacitracin: it may decrease the excretion rate of metheglobinemia associated agents
baclofen: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
capreomycin: it may decrease the excretion rate of metheglobinemia associated agents
carbamazepine: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
diclofenac: it may decrease the excretion rate of metheglobinemia associated agents
diclofenamide: it may decrease the excretion rate of metheglobinemia associated agents
dicyclomine: it may decrease the excretion rate of metheglobinemia associated agents
diflunisal: it may decrease the excretion rate of metheglobinemia associated agents
diflucortolone: it may decrease the excretion rate of metheglobinemia associated agents
chloroprocaine: it may increase the risk of methemoglobinemia associated agents
cinoxacin: it may increase the risk of methemoglobinemia associated agents
ciprofloxacin: it may increase the risk of methemoglobinemia associated agents
doxacurim: it may increase the risk of methemoglobinemia associated agents
estradiol: it may increase the risk of methemoglobinemia associated agents
pyronaridine: it may increase the risk of methemoglobinemia associated agents
perphenazine: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
chlorothiazide: it may increase the risk of methemoglobinemia associated agents
chlorpromazine: it may increase the risk of methemoglobinemia associated agents
ergometrine: it may increase the risk of methemoglobinemia associated agents
when both drugs are combined, there may be a reduced plasma concentration of quinolone antibiotics  
when both drugs are combined, there may be a reduced plasma concentration of quinolone antibiotics  
when both drugs are combined, there may be a reduced plasma concentration of quinolone antibiotics  
when both drugs are combined, there may be a reduced plasma concentration of quinolone antibiotics  
when both drugs are combined, there may be a reduced plasma concentration of quinolone antibiotics
Actions and spectrum:
Hydroxyurea acts as a ribonucleotide reductase inhibitor to inhibit DNA synthesis immediately while leaving ribonucleic acid and protein synthesis unaffected.
Frequency defined
>10%
Nausea
diarrhea
Vomiting
Anemia
Infusion reaction
1-10%
Pneumonia
Herpes zoster reactivation
Bronchospasm
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Hepatic disease
Renal impairment
Pregnancy Warnings:
Pregnancy category: N/A
Lactation: Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Pharmacology:
Hydroxyurea is an antimetabolite used in the treatment of ovarian cancer and chronic myeloid leukemia.
Pharmacodynamics:
Limited information is available.
Pharmacokinetics:
Absorption
The time to reach peak plasma concentration is 1 to 4 hours
Distribution
The volume of distribution is 0.5 L/kg.
Metabolism
Hydroxyurea is metabolized in the liver.
Elimination and excretion
The drug is excreted through urine.
Administration:
It is taken orally as oral dosage form.
Patient Information Leaflet
Generic Name: hydroxyurea
Pronunciation: hye-DROX-ee-yoo-REE-uh
Why do we use Hydroxyurea? Â
Hydroxyurea is used to treat chronic myeloid leukemia (CML), a type of white blood cell cancer. It is also used in combination with radiation therapy to treat advanced head and neck cancers (specifically squamous cell carcinoma). Hydroxyurea works by interfering with the growth of cancer cells, leading to their destruction by the body.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
